MedTrace Logo

Topical IL-1-Ra for Treatment of Corneal Neovascularization

NCT00915590 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

Conditions

  • Corneal Neovascularization

Interventions

DRUG

Placebo

Custom eye drop eye three times a day in both eyes for a period of 6 weeks

DRUG

IL-1Ra

5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks

Sponsors & Collaborators

  • Reza Dana, MD

    lead OTHER

Principal Investigators

  • Reza Dana, MD, MPH, MSc · Massachusetts Eye and Ear Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00915590 on ClinicalTrials.gov